Ensuring Transparency and Quality of Clinical Trial Reporting in Clinical Pharmacology & Therapeutics: Prospective Trial Registration and Compliance with Reporting Guidelines Are Required for all Clinical Trials
Clin Pharmacol Ther
.
2023 Dec;114(6):1153-1157.
doi: 10.1002/cpt.3070.
Authors
D Max Smith
#
1
2
,
Iris K Minichmayr
#
3
,
Joseph F Standing
4
5
,
Kathleen M Giacomini
6
,
Piet H van der Graaf
7
8
,
Richard W Peck
9
10
Affiliations
1
MedStar Health, Columbia, Maryland, USA.
2
Department of Oncology, Georgetown University Medical Center, Washington, DC, USA.
3
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
4
Great Ormond Street Institute of Child Health, University College London, London, UK.
5
Department of Pharmacy, Great Ormond Street Hospital for Children, London, UK.
6
Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
7
Certara, Canterbury, UK.
8
University of Leiden, Leiden, The Netherlands.
9
Department of Pharmacology & Therapeutics, University of Liverpool, Liverpool, UK.
10
Pharma Research & Development (pRED), Roche innovation Center, Basel, Switzerland.
#
Contributed equally.
PMID:
37971383
DOI:
10.1002/cpt.3070
No abstract available
Publication types
Editorial
MeSH terms
Editorial Policies
Humans
Pharmacology, Clinical*
Prospective Studies
Registries
Grants and funding
MR/M008665/1/MRC_/Medical Research Council/United Kingdom